Perspective Therapeutics Brings Lead-212 Alpha-Radioligand Platform to ASCO 2026 With Updates Across VMT-α-NET, VMT01, and PSV359
Perspective Therapeutics presented progress on its three clinical lead-212 (²¹²Pb) targeted alpha-therapy programs at ASCO 2026: [212Pb]VMT-α-NET in somatostatin-receptor-2-positive neuroendocrine tumors, VMT01 in melanoma, and PSV359 in solid tumors. The NET program's earlier Phase 1/2a readout showed a 39% objective response rate in its second cohort and no dose-limiting toxicities at the 5.0 mCi dose, supporting movement toward a registrational trial. The platform pairs a peptide-based targeting vector with a short-range alpha emitter.